Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Patent
1998-02-24
2000-02-22
Kumar, Shailendra
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
560 29, A01N 4734
Patent
active
060281022
ABSTRACT:
According to the present invention, anticonvulsant compounds N-acetyl,N'-benzylglycinamide and N-benzyloxycarbonylglycinamide-Z-glycinamide are disclosed. The present invention also discloses an anticonvulsant pharmaceutical composition comprising an effective amount of at least one active ingredient selected from N-acetyl,N'-benzylglycinamide and N-benzyloxycarbonylglycinamide-Z-glycinamide and a pharmaceutically acceptable carrier or diluent. The present invention provides a method of controlling convulsions in a mammal by administering to the mammal an effective amount of antiepileptic compounds N-acetyl,N'-benzylglycinamide or N-benzyloxycarbonylglycinamide-Z-glycinamide. Combinations of the anticonvulsion compounds can also be administered. The convulsions may be due to epilepsy, febrile convulsions or convulsions precipitated by irritative lesions in the brain. Further the composition may be used to prevent migraine and to treat chronic pain and bipolar disorder.
REFERENCES:
patent: 4439196 (1984-03-01), Higuchi
patent: 4447224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4475196 (1984-10-01), La Zor
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4925678 (1990-05-01), Ranney
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5167616 (1992-12-01), Haak et al.
patent: 5169383 (1992-12-01), Gyory et al.
patent: 5225182 (1993-07-01), Sharma
patent: 5585358 (1996-12-01), Bialer et al.
Benet and Galeazzi (1979). Non-compartmental determination of steady-state olume of distribution. J. Pharm. Sci. 68:1071-1074.
Bialer, et al (1996 ). Progress report on new antiepileptic drugs a summary of the Third Eilat Conference. Epilepsy Res. 25:299-319.
Bialer, et al (1996 ). Pharmacokinetic analysis and antiepileptic activity of tetramethylcyclopropane analogous of valpromide. Pharm. Res. 13:284-289.
Capobianco et al (1996). An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clin Proc 71:1055-66.
Chadwich (ed.) New Trends in Epilepsy Management: The Role of Gabapentin. Royal Society of Medicine Services Ltd., London, 1993.
Clark, et al (1995). Remacemide hydrochloride in R.H. Levy, R.H. Mattson and B.S. Meldrun (eds.) Antiepileptic Drugs, 4th ed. Raven Press, pp. 1035-1044.
Conley and Kohn (1987). Functionalized DL-amino acid derivatives. Potent new agent for the treatment of epilepsy. J. Med. Chem. 30:567-574.
Dreifuss (1987). New anticonvulsant drugs in Epilepsy, Progress in Treatment, M. Dam. S.I. Johannessen, B. Nilsson and M. Sillapaa (eds.), Wiley & Sons, NY, pp. 247-256.
Freed, et al (1979). Anticonvulsant properties of betaine. Epilepsia. 20:209-213.
Freed (1985). Prevention of strychnine-induced seizures and deaths by the N-methylated glycine derivatives betaine, dimethylglycine and sarcosine. Pharmacol. Biochem. Behav. 22:641-643.
"GABA in Nervous System Function", E. Roberts, T.N. Chase, D.B. Tower (eds.), Raven Press, NY (1976).
Garcia and Altman (1997). Chronic pain states: Pathophysiology and medical therapy. Semin Arthritis Rheum 27:1-16.
Geurts, et al., (1998). N-(Benzyloxycarbonyl) glycine Esters and Amides as New Anticonvulsants. J. Med Chem 41:24-30.
Gibaldi and Perrier (1982). Pharmacokinetics, Ed. 2, Marcel Dekker, New York, pp. 445-449.
Gidal et al (1996). Current developments in neurology, Part I: Advances in the pharamcotherapy of headache, epilepsy and multiple sclerosis. Ann Pharmacother 30(11):1272-6.
Gonzales (1995). Central pain: Diagnosis and treatment strategies. Neurology 45(12 Suppl 9):S11-6; Discussion S35-6.
Guay (1995). The emerging role of valproate in bipolar disorder and other psychiatric disorders. Pharmacotherapy 15(5):631-47.
Hadad and Bialer (1995). Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivates of GABA and glycine. Pharm. Res. 12, 905-910.
Hadad and Bialer (1997). Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. Biopharm. Drug Disposit. 18:557-566.
Kohn, et al (1988). Marked stereospecificity in a new class of anticonvulsants. Brain Res. 457:371-375.
Kohn, et al (1990). Preparation and anticonvulsant activity of a series of functionalized .alpha.-aromatic and .alpha.-heteroaromatic amino acids. J. Med. Chem. 33:919-926.
Kohn, et al (1991). Preparation and anticonvulsant activity of a series of functionalized .alpha.-heteroatom-substituted amino acids. J. Med. Chem. 34, 2444-2452.
Krogsgaard-Larsen, et al (1988). Recent advances in GABA agonists, antagonists and uptake inhibitors: Structure activity relationships and therapeutic potential. Advanc. Drug. Res. 17:382-456.
Lambert, et al (1994). Anticonvulsant activities of N-benzyloxycarbonylglycine after parenteral administration. Neuroreport. 5:777-780.
Lambert, et al (1996). Anticonvulsant activity of ester- and amide-type lipid conjugates of glycine and N-benzyloxycarbonylglycine. Eur. J. Pharm. Sci. 4:159-166.
Liu, et al (1990). Potentiation of .gamma.-vinyl GABA (vigabatrin) effects by glycine. Eur. J. Pharmacol. 182:109-115.
McQuay, et al (1995). Anticonvulsant drugs for management of pain: A systemic review. BMJ 311(7012):1047-52.
Mielke (1994). Anticonvulsant therapy for mood disorders. South Med J 87(7):685-8.
Mumford and Canon (1994). Vigabatrin. Epilepsia 35 (Suppl. 5) S25-S28.
Peterson, et al (1990). Potentiation by glycine of anticonvulsant drugs in maximal electroshock seizures in rats. Neuropharmacology, 29:399-409 (1990).
Porter, et al (1984). Antiepileptic drug development program. Cliv. Clin. Quarter. 51:293-305.
Porter (1986). Antiepileptic drugs: efficacy and inadequacy in New Anticonvulsant Drugs, B.S. Meldrum and R.J. Porter (eds.), Libbey, London, pp. 3-16.
Post et al (1996). The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berl) 128(2):115-29.
Puzantian (1996). Criteria for use of valproate in adult psychiatric inpatients and outpatients. Am J Health Syst Pharm 53(10):1187-8.
Roba et al (1986). Milacemide in "New Anticonvulsant Drug", B.S. Meldrum and R.J. Proter (eds.), Jhon Libny, London, pp. 179-190.
Sachs (1996). Bipolar mood disorder: Practical Strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 16(2 Suppl 1):32S-47S.
Salach, et al (1994). Comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity. Pharm. Res. 11:1429-1434.
Seiler and Sarhan (1984). Synergistic anticonvulsant effects of a GABA agonist and glycine. Gen. Pharmacol. 15:367-369.
Silberstein and Lipton (1994). Overview of diagnosis and treatment of migraine. Neurology 44(10 Suppl 7):S6-16.
Swerdlow (1984). Anticonvulsant drugs and chronic pain. Clin Neuropharmacol 7(1):51-82. [n/a--will mail in].
Toth and Lajtha (1984). Glycine potentiates the action of some anticonvulsant drugs in some seizure models. Neurochem. Res. 8:1711-1718.
Vanvalkenburg et al (1992). New uses of anticonvulsant drugs in psychosis. Drugs 44(3):326-35.
Wood, et al (1988). Amplification by glycine of the effect of the GABA transport inhibitor THPO on synaptosomal GABA level. Neurochem. Res. 13:917-921.
Yamaoka, et al (1978). Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6:547-558.
Yamaoka (1986). Methods for pharmacokinetic analysis for personal computers. Edition 2, Nanko-D Led., Tokyo, pp. 145-175. [n/a--will mail in].
Bialer Meir
Dagan Arie
Sherbel Sussan
Kumar Shailendra
Yissum Research Development Company of the Hebrew University of
LandOfFree
Anticonvulsant drugs and pharmaceutical compositions thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticonvulsant drugs and pharmaceutical compositions thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticonvulsant drugs and pharmaceutical compositions thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-520918